

#### Vaccines and Global Health: The Week in Review 09 December 2023 :: Issue 730 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <u>https://centerforvaccineethicsandpolicy.net</u>. This blog allows full text searching of over 27,000 entries. Comments and suggestions should be directed to David R. Curry, MS Editor and Executive Director Center for Vaccine Ethics & Policy david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: <u>Milestones, Perspectives</u>
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: <u>Pre-Print Servers</u>
- :: <u>Think Tanks</u>

#### Milestones, Perspectives

.....

#### Polio

Gates Foundation and Agence Française de Développement Partner to Support Last Mile Polio Eradication in Pakistan and to Build more Climate Resilient Health Systems PARIS, FRANCE (December 5, 2023) - Bill Gates, co-chair of the Bill & Melinda Gates Foundation and Remy Rioux, CEO of the Agence Française de Développement (AFD) announced today **new** commitments that implement the <u>Paris Pact</u> principles combining official development assistance and private investment and support the objective of global polio eradication by 2026.

The funding—an up to  $\in$ 55 million concessional loan, with an up to  $\in$ 20 million principal buy-down from the Gates Foundation will support Pakistan's national health institutions and the Pakistan Polio Eradication Initiative to recover following impacts from the devastating floods in August 2022.

#### Supporting Healthcare System Resilience to Climate Change

The floods in 2022 were Pakistan's worst natural disaster in decades highlighting multiple climatic vulnerabilities faced by the country. The human toll was tragically high with one third of the country submerged underwater, approximately 15,000 killed or injured and 8 million displaced. Damage to infrastructure was also catastrophic: over 2 million homes, 13,000 kilometers of highways, 439 bridges and 888 health centers were damaged or destroyed leaving the populations affected by the floods without access to healthcare. Flooding also triggers an upsurge in water-borne diseases (severe diarrhea and cholera) and diseases carried by insects (dengue fever and malaria).

The new project is a contribution to the Pakistani efforts to chart progress towards a climate resilient health system capable of anticipating, recovering from, and adapting to climate-related shocks and stresses, so as to bring about sustained improvements in population health, despite an unstable climate. By supporting the Pakistan Polio Eradication Programme (PEI), through the World Health Organization (WHO), in immunization activities, disease surveillance, polio campaign monitoring and other technical areas, the AFD investment will enhance systems able to target climate-sensitive diseases and their risk sources. Importantly, this funding will also provide further support for female polio health care workers, whose efforts and experiences are central to Pakistan's success against polio and other diseases.

#### Pakistan Polio Eradication Program

Pakistan has reported five cases of paralysis from polio so far this year. The virus has also been detected in sewage water in 20 districts in the four major provinces, reaffirming that polio continues to pose a threat to children living in poor sanitary conditions with low immunity and poor nutrition...

Dr. Nadeem Jan, Federal Minister of National Health Services Regulations & Coordination in Pakistan emphasized the significance of this funding and polio infrastructure in Pakistan: "We welcome the support of the French Government and the Gates Foundation as we near the finish line on polio eradication. The Pakistan Polio Eradication Programme is a vital part of our healthcare system and investing in polio builds the country's overall health system."...

Since 1994, the Pakistan Polio Eradication Programme has been fighting to end the crippling poliovirus from the country. The national initiative is driven by trained and dedicated polio workers, the largest <u>surveillance</u> network in the world, quality data collection and analysis, behavioral change communication, state of the art laboratories, and some of the best epidemiologists and public health experts in Pakistan and the world.

"Thank you to the Government of France and the Government of Pakistan for their continued leadership in the fight to end polio." said Mark Suzman, CEO of the Bill & Melinda Gates Foundation. "From France's commitment to the Global Polio Eradication Initiative last year to today's new financing partnership between the French Development Agency and the Government of Pakistan, these additional resources are essential to ensuring no child suffers from this devastating disease again."...

.....

.....

# Gavi expands portfolio, introduces new vaccine programmes to save more lives and support child health

- Countries can now submit plans to introduce diphtheria, tetanus and pertussis (DTP)containing vaccine boosters (DTP boosters) and the six-in-one hexavalent vaccine
- Gavi and partners are also working towards expanding the portfolio of offerings in 2024, including the hepatitis B birth dose and rabies vaccines
- Thabani Maphosa, Managing Director of Country Programmes Delivery, Gavi: "By continually expanding our vaccine portfolio, and targeting the children and communities most frequently left behind, we can save more lives, support child and adolescent health through vaccinations beyond infancy, and make way to provide other important services."

Geneva, 4 December 2023 – Countries eligible for Gavi support can <u>now apply</u> to introduce diphtheria, tetanus and pertussis (DTP)-containing vaccine boosters (<u>DTP boosters</u>) – as well as to switch to <u>hexavalent</u> vaccine – a six-in-one vaccine that combines the pentavalent vaccine (diphtheria, tetanus, whole-cell pertussis [DTwP], hepatitis B and Haemophilus influenzae type b) with inactivated polio vaccine (IPV).

These new programmes, part of Gavi's commitment to leave no child behind with

**immunisation**, will enable countries to protect more children against common childhood illnesses, use public health resources more efficiently and strengthen the reach of health systems. Combined, the three pathogens, DTP, are estimated to kill about <u>110,000 people</u> annually, with the greatest burden in Asia and sub-Saharan Africa (mainly children aged one to four years). **The DTP boosters will be vital in protecting children who have not received any routine vaccines, are under-immunised or come from missed communities**. Low immunisation coverage makes vulnerable communities susceptible to recurrent vaccine-preventable disease outbreaks, worsening health and development outcomes. Providing these boosters also reinforces a life-course approach to vaccination and can strengthen vaccination contacts during the second year of life and in school health programmes.

The Gavi Board approved the whole-cell pertussis <u>hexavalent vaccine</u> in June 2023. This combination vaccine is expected to help countries deliver protection against all six diseases more efficiently and reduce programmatic challenges due to multiple vaccines and injections – which would reduce the burden on children, caregivers and health care workers and make it easier to reach un- and under-immunised children. In support of <u>polio eradication</u>, combining IPV with pentavalent increases opportunities for under-immunised children to receive sufficient IPV doses,

and providing IPV as part of a combination vaccine with other core antigens ensures streamlined integration into national immunisation programmes, as we look toward a post-polio world...

.....

#### Vaccine Manufacturing – Africa

More than US\$ 1.8 billion in support for African vaccine manufacturing, catching up missed children and pandemic preparedness approved as Gavi Board steps up efforts to tackle backsliding and fight health emergencies

- Gavi's Board today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument that will make up to US\$ 1 billion available to support sustainable vaccine manufacturing in Africa
- Efforts to translate pandemic learnings into concrete action further include the establishment of a US\$ 500 million First Response Fund to ensure immediate financing for vaccine response in the event of a future pandemic, as well as extraordinary support for countries to close routine immunisation gaps created during the COVID-19 pandemic
- The Board approved the inclusion of the new multivalent meningococcal vaccine into the Gavi portfolio, as well as the shortlist of new vaccines for Gavi's next Vaccine Investment Strategy
- The Government of France and Africa CDC, alongside with European and international partners, will co-host a high level event in June 2024 to officially launch the AVMA mechanism as well as Gavi's investment case to support its next replenishment

Geneva/Accra, 7 December 2023 – The Board of Gavi, the Vaccine Alliance today announced a series of decisions that will help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to future health emergencies. The decisions were taken during a two-day meeting hosted by the Government of Ghana in Accra, Ghana, from 6-7 December.

#### Concrete action in support of African vaccine manufacturing, future pandemic response

Following more than 18 months of close collaboration between Gavi, the African Union and Africa CDC, the Board today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA). AVMA is an innovative financing mechanism aimed at establishing a sustainable African vaccine manufacturing industry capable of improving the region's resilience in the face of pandemics, outbreaks and other health emergencies as well as the health of global vaccine markets. AVMA was designed through an extensive consultation process that involved partners, donors, industry, civil society, and others.

Gavi, as one of the largest purchasers of vaccines in the world, is thus sending a powerful signal to global markets that it will support African vaccine manufacturing. **AVMA aims to make up to US\$ 1 billion available to manufacturers at key moments in the development process as a way of helping offset high start-up costs and provide assurance of demand**. By focusing on "priority" antigens, product profiles, and vaccine platforms, as well as constructing clear incentives for both "fill and finish" and drug substance production, AVMA will also support global vaccine markets by targeting clear unmet needs and help establish a thriving, sustainable, end-to-end African vaccine manufacturing ecosystem.

**AVMA** is the final pillar of Gavi's regional manufacturing strategy, <u>with the first three</u> <u>pillars approved by the Board in December 2022</u>. With this Board approval, Gavi can now consult widely on the final operational framework for AVMA, including the establishment of an inclusive steering committee, and processes for governance, monitoring and course-correcting as needed. These final pieces will be reviewed by the Board in June 2024, following which AVMA will be officially launched in that same month during an event co-hosted by France and Africa CDC, alongside with European and international partners.

Building even further on the theme of ensuring learnings from the COVID-19 pandemic are met with concrete actions, the **Board also approved a US\$ 500 million investment in a First Response Fund, part of a broader Day Zero Financing Facility, to ensure financing is immediately available from the start of a future pandemic. This decision responds to one of the challenges of the COVID-19 pandemic, where it took time to fundraise in support of the effort to ensure equitable access to vaccines,** slowing down the ability to respond quickly to countries' needs, and contributing to vaccine inequity. This investment is combined with Board approval to dedicate US\$22 million to support pandemic prevention, preparedness and response activities across a broad coalition of vaccine-related partners and processes, including countries, civil society, strengthening immunisation and outbreak response activities, and aligning with international pandemic-related deliberations and mechanisms. This effort seeks to ensure a coordinated playbook for potential pandemic response, coverage of any gaps, and increased transparency and knowledge sharing across the full ecosystem. This Board decision will help create an inclusive approach, ahead of a potential future emergency, to ensuring all partners are ready to contribute in a coordinated response.

"Today's historic decisions illustrate the very best of our Alliance – collaboration across the full range of immunisation partners, constantly seeking to learn and improve, and most importantly, taking concrete action," said Professor José Manuel Barroso, Chair of the Gavi Board. "Gavi has worked closely with the countries, the African Union, Africa CDC, G7, G20, and other donors, WHO, UNICEF, civil society, industry, and experts to put into place innovative mechanisms that have the power to reshape our approach to regional manufacturing and pandemic response, and we are grateful for the continued commitment of our Board to the effort to ensure no one is left behind with immunisation."...

#### .....

#### A Breakthrough for the African Vaccine Manufacturing

#### Africa CDC

Accra, Ghana, 8th December 2023 – The Africa Centres for Disease Control and Prevention (Africa CDC) has welcomed the announcement from The Global Vaccine Alliance (GAVI) Board for the establishment of the African Vaccine Manufacturing Accelerator (AVMA), a financing mechanism aimed at creating a sustainable vaccine manufacturing industry in Africa.

The AVMA is a financing mechanism aimed at creating a sustainable vaccine manufacturing industry in Africa and will make up to US\$ 1 billion available to support vaccine manufacturing in Africa.

In 2021, the African Union Heads of States and Governments established The Partnerships for African Vaccine Manufacturing (PAVM) under the Africa CDC. The goal of the PAVM is to enable the African vaccine manufacturing industry to develop, produce, and supply over 60 per cent of the total vaccine doses required on the continent by 2040. This is up from less than 1 per cent today, with interim goals of 10 per cent by 2025 and 30 per cent by 2030. The collaboration has seen several vaccine manufacturing projects taking shape, and others are in the works to guarantee self-reliance in Africa should any health emergency or outbreak hit the continent.

Speaking after the announcement in Accra, Dr. Jean Kaseya, Africa CDC Director General, said, "Today is a significant moment for Africa. The targeted USD 1 Billion from GAVI to African Manufacturers is a game changer for the continent and advances our efforts towards vaccine selfreliance. Africa CDC remains determined that Africa should produce its vaccine and protect the lives of all Africans. The African Union has set a target for the continent to produce 60% of the vaccines needed by 2040; AVMA is indeed an accelerator towards that ambition. Among the COVID-19 lessons, working together is a way forward. GAVI has been an incredible partner in this; we will continue to advance together on this journey of self-reliance. Together, we are united with a mission for vaccine equity."...

:::::: ::::::

NTDs

Global Donors Pledge Over US\$777 Million to Defeat Neglected Tropical Diseases and Improve the Lives of 1.6 Billion People at the Reaching the Last Mile Forum at COP28

DUBAI, UNITED ARAB EMIRATES (December 3, 2023): Global donors at the 2023 *Reaching the Last Mile Forum* today pledged a collective US\$777.2 million to help control, eliminate, and eradicate neglected tropical diseases (NTDs), in a landmark push to accelerate progress towards achieving the goals outlined in the World Health Organization's 2030 roadmap on NTDs.

Uniting efforts with NTD-endemic countries, donors answered the urgent call to step up the fight against NTDs in the face of climate change, and to work together to improve the lives of the 1.6 billion people worldwide affected by these devastating yet preventable diseases.

The pledging event was hosted by Reaching the Last Mile (RLM), the global health initiative driven by the philanthropy of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, in partnership with the Bill & Melinda Gates Foundation. The forum took place on the first ever Health Day during the United Nations Climate Change Conference (COP28)...

His Highness Sheikh Abdullah bin Zayed Al Nahyan stated: "The UAE is proud to host this pivotal conference and expresses gratitude to all those who have seized the opportunity to renew their commitment to end neglected tropical diseases. **Today's demonstration of global solidarity reflects a shared determination to deliver a better and more dignified future for all**. Incredible progress over the last two decades has proved that a world free of NTDs is an achievable goal. We warmly thank governments, donors, and partners for standing with us as we strive to achieve it."

Reaching the Last Mile joined with the Gates Foundation and global partners to announce a milestone expansion of the Reaching the Last Mile Fund (RLMF) from \$100M to \$500M. The expansion will increase the reach of the fund from seven countries to 39 across Africa and Yemen, with the audacious goal of eliminating two NTDs, lymphatic filariasis and onchocerciasis (river blindness), from the continent of Africa.

"Climate change is inextricably linked to poverty and diseases affecting millions," said Bill Gates, Cochair of the Bill & Melinda Gates Foundation. "That is why funding for lifesaving healthcare is critical and why we're joining global partners to build on the tremendous progress of the Reaching the Last Mile Fund to date, and accelerate the elimination of LF and river blindness across Africa and beyond."...

The funding builds on the pioneering success of the RLMF, which launched in 2017 as a 10-year, multi-donor fund, to establish a model for eliminating the two diseases in sub-Saharan Africa. His

Highness Sheikh Theyab bin Mohamed Al Nahyan said: "Today we reaffirm our pledge to eliminate these diseases of poverty, and save and improve lives worldwide. Climate change is already affecting the patterns of infectious diseases and risking the tremendous gains countries have made to date...

# Reaching the Last Mile's new \$100m commitment, matching the Gates Foundation's \$100m commitment, represents a five-fold increase over the contributions made, respectively, to the fund at its launch.

Further contributions from country and donor partners including Sierra Leone, the Carter Center, Sightsavers, the Children's Investment Foundation Fund (CIFF), The Helmsley Charitable Trust, the END Fund, and Abu Dhabi National Insurance Company will see RLMF significantly broaden its scope, with the aim of ensuring over 350 million people no longer require treatment for these diseases by 2030....

.....

#### IHR

#### 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005)

*On 7 December, IFPMA submitted a statement to the 6<sup>th</sup> Meeting of the Working Group on Amendments to the International Health Regulations (2005)(WGIHR),* 

The innovative pharmaceutical industry remains steadfast in our commitment to constructively work with the WGIHR. As we approach the end of the year and to ensure cross-instrumental cohesion, we stress the critical need for alignment with the Intergovernmental Negotiating Body (INB).

It is in all our interests to ensure that the International Health Regulations (IHR) amendments are fit for purpose and include pragmatic actions to strengthen Member States' preparedness and response to public health events with the risk of international spread. Toward this end, the current direction of travel should be course corrected, avoiding duplication of issues in the WGIHR and INB and ensuring strict adherence to the WGIHR's technical mandate and scope.

Just as global health security and equitable access are two sides of the same coin, the WGIHR and INB must complement efforts, with the WGIHR strengthening country capacities to prevent, prepare for, and respond to public health events before they become public health emergencies of international concern, and with equity at the heart of the INB.

## To modernize the IHR, the industry calls for Member States to build upon lessons learned from COVID-19 and bolster proven – not ideological – strategies, including:

- 1. Raising the alarm early by ensuring the rapid sharing of outbreak information and immediate access to pathogens and genetic data
- 2. Enabling the innovation ecosystem, including protecting incentives on intellectual property, to reinforce the pipeline for needed medical countermeasures
- 3. Fostering multi-stakeholder partnerships and dialogue, including with the private sector, to ensure balanced and implementable approaches.

We emphasize our immediate readiness to collaborate with the WGIHR.

:::::: :::::::

#### **Polio – PHEIC**

#### Polio this week as of 06 Dec 2023 - GPEI

#### Headlines [Selected]

:: "Interrupting poliovirus transmission remains a core focus for the Government of Pakistan, and thanks to the heroic efforts of community health workers, global partners and contributors like the Islamic Development Bank (IsDB) and the Foundation, we have pushed the virus to the brink of eradication," – H.E. Dr. Nadeem Jan, Minister of National Health Services Regulations and Coordination, Pakistan. <u>Read more</u>...

#### Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1 case and 20 WPV1-positive environmental samples
- Algeria: one cVDPV2 positive environmental sample
- DR Congo: seven cVDPV1 cases and one cVDPV2 case
- Kenya: two cVDPV2 positive environmental samples
- Mauritania: one cVDPV2-positive environmental sample
- Nigeria: 12 cVDPV2 cases and five cVDPV2 positive environmental samples
- Somalia: one cVDPV2 positive environmental sample

### .....

#### **Coronavirus** [COVID-19]

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

#### Numbers at a glance

Last update: <b>06 Dec 2023</b>	
Confirmed cases ::	772 138 818
Confirmed deaths ::	6 985 964
Vaccine doses administered ::	13 595 721 080

:::::

#### Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 09 Dec 2023]

:: 70.6% of the world population has received at least one dose of a COVID-19 vaccine.

- :: <u>13.53 billion doses</u> have been administered globally, and <u>4,667</u> are now administered each day.
- :: <u>32.9%</u> of people in low-income countries have received at least one dose.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: <u>Pre-Print Servers</u>

#### WHO & Regional Offices [to 09 Dec 2023]

https://www.who.int/news

Selected News/Announcements/Statements 8 December 2023 Departmental news France signs agreements to support WHO's work

#### 7 December 2023 News release

<u>Governments continue discussions on pandemic agreement negotiating text</u> Sustainable production of pandemic-related tools, boosting country health system capacities, financing solutions and misinformation among subjects discussed by WHO Member States

Governments continued their work to negotiate and draft an <u>agreement</u> to strengthen global pandemic prevention, preparedness and response to prevent a repeat of the health, social and economic impacts that were caused by the COVID-19 pandemic.

This seventh meeting of the Intergovernmental Negotiating Body (INB) ended on 6 December 2023 at the World Health Organization (WHO) headquarters in Geneva. Over two sessions, running from 6–10 November and 4–6 December, governments completed the review of the <u>pandemic</u> <u>agreement negotiating text</u> presented by the Member State-appointed Bureau of the INB.

Delegations from WHO Member States discussed a wide range of critical elements, including pandemic and public health surveillance, One Health and boosting pandemic preparedness, readiness and resilience in countries.

Equity and the right to health are among the guiding principles of the draft text of the proposed pandemic agreement under discussion. In this light, governments discussed the sustainable production of pandemic-related products; the transfer of technology and know-how to produce such items; and a multilateral system for access to pathogens and the sharing of benefits derived from them, such as vaccines and other pandemic-related products, to support prevention, preparedness and response.

Among other topics considered by Member States were the transfer to developing countries of technical and scientific expertise, and technology support, and sustainable financing to strengthen pandemic prevention, preparedness and response...

6 December 2023 Departmental news

Using a costing tool for sustaining genomics for pandemic and epidemic prone pathogens in Namibia

5 December 2023 Departmental news

Reflections from the second World Local Production Forum, November 2023

#### 4 December 2023 Statement

WHO appeals for protection of the health system from further attacks and degradation of its capacity

Once again, nowhere is safe in Gaza. WHO is gravely concerned about the resumption of hostilities, including heavy bombardment in Gaza, and reiterates its appeal to Israel to take every possible measure to protect civilians and civilian infrastructure, including hospitals, as per the laws of war.

We have seen what happened in northern Gaza. This cannot be the blueprint for the south. Gaza cannot afford to lose another hospital as health needs continue to soar.

As more civilians in southern Gaza receive immediate evacuation orders and are forced to move, more people are being concentrated into smaller areas, while the remaining hospitals in those areas run without sufficient fuel, medicines, food, water, or protection of health workers.

WHO and other partners are less able to provide support, given dwindling access to our supplies or any assurance of safety when we move supplies or staff...

4 December 2023 Departmental news

Uganda takes the lead: piloting the Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research

#### 4 December 2023 Departmental news

Global partners pledge US\$ 777 million to combat neglected tropical diseases

::::::

#### **WHO Regional Offices**

Selected Press Releases, Announcements

#### WHO African Region

:: <u>WHO Africa welcomes new commitment by global partners to end neglected tropical diseases</u> 06 December 2023

#### WHO Region of the Americas PAHO

:: 7 Dec 2023

PAHO Director meets with high-level authorities in Uruguay, highlights strengths of country's health system

Montevideo, 6 December 2023 (PAHO) - The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, visited Uruguay this week where he met with senior government officials, legislators and deans of medical schools. The PAHO Director also visited hospitals and health centers and attended the Regional Forum: Alliance for Primary...

:: 5 Dec 2023

At COP28, PAHO Assistant Director calls for regional solidarity to address health impacts of "triple planetary crisis" of climate change, biodiversity loss, and pollution

Dubai, United Arab Emirates, 4 December 2023 (PAHO) – The Assistant Director of the Pan American Health Organization (PAHO), Dr. Rhonda Sealey-Thomas, has urged countries of the Americas to ensure the health impacts of climate change are taken on board as they continue to rebuild and strengthen health systems in the aftermath of the COVID-19...

:: 4 Dec 2023

PAHO, IDB and World Bank launch alliance to strengthen primary health care in the Americas

Montevideo, Uruguay, December 4, 2023– The Pan American Health Organization (PAHO), the Inter-American Development Bank (IADB) and the World Bank (WB) today launched the Alliance for Primary Health Care in the Americas, a collaboration to boost investment, innovation and implementation of policies and initiatives aimed at transforming health...

#### WHO South-East Asia Region SEARO

No new digest content identified.

#### WHO European Region EURO

No new digest content identified.

#### WHO Eastern Mediterranean Region EMRO

:: <u>WHO strengthens health emergencies response in northwest Syria</u> 5 December 2023

:: <u>WHO appeals for protection of the health system from further attacks and degradation of its</u> <u>capacity</u> 4 December 2023

#### WHO Western Pacific Region

:: <u>WHO strengthens health emergencies response in northwest Syria</u> 5 December 2023

:: WHO appeals for protection of the health system from further attacks and degradation of its capacity \_4 December 2023

#### :::::

#### WHO - Emergency situation reports

#### <u>Multi-country outbreak of cholera, External situation report #9 - 7 December 2023</u> Overview

Since the last multi-country cholera situation report published on 2 November 2023 (including data up to 15 October), no additional countries have reported new cholera or acute watery diarrhoea outbreaks as of 15 November 2023. However, new outbreaks have been reported within affected countries. In total, 29 countries have reported cases since 1 January 2023. The WHO African Region is the most impacted, with 16 countries reporting cases since the beginning of the year.

Preliminary 2023 data from Member States indicate that the number of cases reported this year as of 15 November has surpassed that of 2022, with over 610 000 cases and 3500 deaths, corresponding to a case fatality rate (CFR) of 0.6%. This finding must be interpreted with caution given that 2023 data are not directly comparable to the more comprehensive official reports to WHO from previous years.

Given the extensive number of outbreaks, their widespread distribution, and the current shortage of vaccines and other resources, WHO continues to assess the risk at the global level as very high.

#### .....

#### Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

8 December 2023 | Anthrax - Zambia

#### .....

#### Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record No new issue identified.

#### .....

#### **New WHO Publications**

https://www.who.int/publications/i Selected 8 December 2023 A checklist for respiratory pathogen pandemic preparedness planning

Overview

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans. It presents suggested priority actions that countries can take now in order to be better prepared for a pandemic. It is in-line with the Preparedness and resilience for emerging threats (PRET) approach (<u>web link</u>) and in conjunction with PRET module 1: planning for respiratory pathogen pandemics (<u>web link</u>).

::::: :::::

#### USA – HHS, FDA, CDC

#### HHS

News No new digest content identified.

#### **FDA**

Press Announcements December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

#### **FDA VRBPAC**

Advisory Committee Calendar No new meetings scheduled.

#### CDC/ACIP [U.S.] [to 09 Dec 2023]

http://www.cdc.gov/media/index.html Latest News Releases No new digest content identified.

#### ACIP Meetings

Next ACIP Meeting No new meetings scheduled.

#### **MMWR Weekly**

https://www.cdc.gov/mmwr/index2023.html December 8, 2023 / No. 49

PDF of this issue

- Progress in Immunization Safety Monitoring Worldwide, 2020–2022
- Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory \_ Committee on Immunization Practices — United States, 2023
- Notes from the Field: Undiagnosed Tuberculosis During Pregnancy Resulting in a Neonatal Death — United States, 2021
- Notes from the Field: Responding to the Wartime Spread of Antimicrobial-Resistant Organisms \_ — Ukraine, 2022

:::::

::::::

#### Europe

#### **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news

News & Press Releases

Global regulators strengthen efforts to ensure continuous availability of safe and highquality medicines

Collaboration between medicines regulators is paving the way towards a global Pharmaceutical Quality Knowledge Management System (PQ KMS).

8 December 2023

#### \*\*\*\*\*

#### European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en News/Updates/Reports/Publications [Selected] Rising rates of sexually transmitted infections across Europe News - 8 Dec 2023

ECDC assesses risk associated with ongoing mpox epidemic in the Democratic Republic of the Congo News story - 5 Dec 2023

.....

Africa CDC [to 09 Dec 2023] http://www.africacdc.org/ Press Releases, Statements [Selected] Press Releases A Breakthrough for the African Vaccine Manufacturing 8 December 2023

Press Releases Accelerating investment in community health workforce programs in Africa 6 December 2023

.....

China CDC http://www.chinacdc.cn/en/

#### National Health Commission of the People's Republic of China [to 09 Dec 2023]

<u>http://en.nhc.gov.cn/</u> *News No new digest content identified.* 

#### National Medical Products Administration – PRC [to 09 Dec 2023]

http://english.nmpa.gov.cn/ News

China urges enhanced medical care for children's respiratory diseases

2023-12-04

The National Health Commission of China has issued a circular urging maternal and child care institutions to increase the resources for diagnosing and treating respiratory diseases in children.

#### Vaccinations still vital to curb illness spread

2023-12-04

The recent surge of respiratory illnesses in China is fueled by known pathogens, and vaccination efforts are still vital to stem the spread, medical experts said on Saturday.

#### China CDC <u>Weekly Reports: Current Volume (5)</u> 2023-12-08 / No. 49

View PDF of this issue

- <u>Announcements: The 28th United Nations Climate Change Conference (COP28) November 30</u> to December 12, 2023
- <u>Methods and Applications: Nowcasting and Forecasting Seasonal Influenza Epidemics China,</u> 2022–2023

.....

#### Contents [click to move among sections]

:: <u>Milestones, Perspectives</u> :: <u>WHO</u> :: <u>Organization Announcements</u> :: <u>Journal Watch</u> :: <u>Pre-Print Servers</u>

.....

#### **Organization Announcements**

Paul G. Allen Frontiers Group[to 09 Dec 2023]https://alleninstitute.org/news-press/NewsNo new digest content identified.

#### BMGF - Gates Foundation [to 09 Dec 2023]

https://www.gatesfoundation.org/ideas/media-center Press Releases and Statements Press release Dec 05, 2023 Gates Foundation and Agence Française de Développement Partner to Support Last Mile Polio Eradication in Pakistan and to Build more Climate Resilient Health Systems

Press release Dec 03, 2023 Global Donors Pledge Over US\$777 Million to Defeat Neglected Tropical Diseases and Improve the Lives of 1.6 Billion People at the Reaching the Last Mile Forum at COP28

#### Bill & Melinda Gates Medical Research Institute [to 09 Dec 2023]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications No new digest content identified. CARB-X [to 09 Dec 2023] https://carb-x.org/ News No new digest content identified.

#### CEPI – Coalition for Epidemic Preparedness Innovations [to 09 Dec 2023]

http://cepi.net/

Latest News

#### Charles River Laboratories joins CEPI's global vaccine assessment network

The global pharmaceutical company becomes the latest member of CEPI's Centralised Laboratory Network created to standardise and speed up the development of epidemic and pandemic vaccines. *News* 07 Dec 2023

### <u>CEPI partners with biotech Jurata Thin Film to create needle-free mRNA vaccines and improve access</u>

Thermostable vaccine technology could end the need for frozen vaccine storage, expanding global access to mRNA LNP vaccines and supporting future pandemic response efforts. *End Pandemics* 05 Dec 2023

### **CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 09 Dec 2023]

<u>https://cioms.ch/</u> *News; Publications; Events* 

<u>CIOMS Working Group report on Good Governance Practice in Research Institutions</u> <u>now published</u>

The aim of <u>this report</u> is to help research institutions better fulfil their responsibilities in terms of protecting human research participants and their communities, involving and engaging them in the research processes, and guaranteeing the pertinence and quality of research while making the best use of available resources.

#### DARPA – Defense Advanced Research Projects Agency [U.S.] [to 09 Dec 2023

<u>https://www.darpa.mil/news</u> *News No new digest content identified.* 

#### Duke Global Health Innovation Center [to 09 Dec 2023]

<u>https://dukeghic.org/</u> *News No new digest content identified.* 

#### **EDCTP** [to 09 Dec 2023]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

06 December 2023 <u>PrEPVacc study reports that experimental HIV vaccine regimens likely to be ineffective</u> <u>in preventing HIV acquisition</u>

04 December 2023 Benin and Somalia join EDCTP Association

#### Emory Vaccine Center [to 09 Dec 2023]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### European Vaccine Initiative [to 09 Dec 2023]

<u>http://www.euvaccine.eu/</u> *Latest News, Events No new digest content identified.* 

#### Evidence Aid [to 09 Dec 2023]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use. http://www.evidenceaid.org/ Resources [Selected] Use and outcomes of maternal and child healthcare services by undocumented migrants in Europe Added December 9, 2023

Migration and severe maternal outcomes in high-income countries Added December 8, 2023

Vaccination among disadvantaged, isolated, and difficult-to-reach communities in the WHO European Region Added December 6, 2023

Tools and checklists for evaluating hospital disaster preparedness (search done in 2013) Added December 5, 2023

Fondation Merieux [to 09 Dec 2023] http://www.fondation-merieux.org/ News, Events No new digest content identified.

Gavi [to 09 Dec 2023] https://www.gavi.org/ News Releases 7 December 2023 More than US\$ 1.8 billion in support for African vaccine manufacturing, catching up missed children and pandemic preparedness approved as Gavi Board steps up efforts to tackle backsliding and fight health emergencies

4 December 2023 Gavi expands portfolio, introduces new vaccine programmes to save more lives and support child health

#### GE2P2 Global Foundation [to 09 Dec 2023]

<u>www.ge2p2.org</u>

*News/Analysis/Publications-Digests/Statements* 

:: Vaccines and Global Health: The Week in Review - Current edition

:: Informed Consent: A Monthly Review - December 2023

:: <u>Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest</u> – Oct 2023

:: Public Consultations Watch :: Global Calls for Input/Public Comment – 24 Oct 2023 – Issue 09

**GHIT Fund** [to 09 Dec 2023] https://www.ghitfund.org/newsroom/press *Press Releases* No new digest content identified.

#### Global Fund [to 09 Dec 2023].

https://www.theglobalfund.org/en/news/

News & Stories

03 December 2023

The Global Fund Applauds Ireland's Additional Pledge, Bringing Total Contribution to €65.75 Million

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) commends Ireland's additional €750,000 pledge, bringing the Republic's total contribution to €65.75 million for the upcoming three-year period.

03 December 2023 <u>Reaching the Last Mile Welcomes Collective Commitment to Boost Support to</u> <u>Community Health Workers</u>

Reaching the Last Mile – a portfolio of global health programs, investments, and initiatives working to end preventable diseases that affect the world's most vulnerable communities– welcomes the commitment made by a coalition of partners to accelerat...

02 December 2023

The Global Fund to Spend 70% of Its Funding in Most Climate-vulnerable Countries

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) announced during the World Climate Summit at COP28 in Dubai that more than 70% of its funding – over US\$9 billion over the next three years – will be spent in the 50 most clima...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 09 Dec 2023] https://www.glopid-r.org/news/

News No new digest content identified.

Hilleman Laboratories [to 09 Dec 2023]

http://www.hilleman-labs.org/ News & Insights No new digest content identified.

#### HHMI - Howard Hughes Medical Institute [to 09 Dec 2023]

<u>https://www.hhmi.org/news</u> *Press Room No new digest content identified.* 

Human Immunome Project [nee Human Vaccines Project] [to 09 Dec 2023] http://www.humanvaccinesproject.org/ News No new digest content identified.

IAVI [to 09 Dec 2023] https://www.iavi.org/ Latest News, Features December 6, 2023 Meet The Scientist podcast: An interview with Joyeeta Mukherjee, Ph.D., associate director at IAVI, on the intersection of community and science

**INSERM** [to 09 Dec 2023] https://www.inserm.fr/en/home/ *Press Releases No new digest content identified.* 

International Coalition of Medicines Regulatory Authorities [ICMRA] http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research 8 December 2023 ICMRA-ICH-IPRP-PICS Joint Work Plan to Advance Development of a Regulatory PQKM Capability

8 December 2023 Update - PQKMS ICMRA-industry virtual workshop summary report

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 09 Dec 2023] https://www.ich.org/page/press-releases

News/Pubs/Press Releases [Selective] No new digest content identified. <u>ICRC</u> [to 09 Dec 2023] <u>https://www.icrc.org/en/whats-new</u> *What's New* [Selected] https://www.icrc.org/en/unga78-annual-statement-ihl <u>IHL seeks to limit the humanitarian consequences of armed conflicts</u>

Mr President, Excellencies, Distinguished Delegates, We meet this year at a time of significant humanitarian challenges, and armed conflict is at the heart of these challenges. Thousands of our colleagues are mobilized in contexts around the world to r 08-12-2023 | Statement

#### IFFIm

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

IFRC [to 09 Dec 2023] http://media.ifrc.org/ifrc/news/press-releases/ Press Releases [Selected] Press release 08/12/2023 COP28: 'Inaction on adaptation risks lives'

**Institut Pasteur** [to 09 Dec 2023] https://www.pasteur.fr/en/press-area

Press Documents

Press release 06.12.2023

Plasmodium vivax malaria: infections may be largely underestimated in sub-Saharan Africa

Researchers from the Institut de Parasitologie et de Pathologie Tropicale at the University of Strasbourg and the...

Press release 05.12.2023

COVID-19: the persistence of SARS-CoV-2 in the lungs and the role of innate immunity

One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory...

#### ISC / International Science Council [to 09 Dec 2023]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils. News, Blogs News/Events [Selected] No new digest content identified.

#### International Union of Immunological Societies (IUIS)

<u>https://iuis.org/</u> *News/Events [Selected] No new digest content identified.* 

**IVAC** [to 09 Dec 2023] https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html Updates; Events No new digest content identified.

IVI [to 09 Dec 2023] http://www.ivi.int/ IVI News & Announcements Dr. Jae Ouk Kim receives Health Minister's Award for contributions to infectious disease education

**IVI-WHO Consultation on Salmonella Combination Vaccines** 

Johns Hopkins Center for Health Security [to 09 Dec 2023] https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

MSF/Médecins Sans Frontières\_ [to 09 Dec 2023] http://www.msf.org/ Latest [Selected Announcements] Gaza-Israel war Gaza: The Security Council must end its complicity in the ongoing carnage Press Release 8 Dec 2023

Gaza-Israel war <u>MSF calls US veto of Gaza ceasefire resolution "a vote against humanity"</u> Statement 8 Dec 2023

*Libya* <u>MSF report on abuse in Abu Salim and Ain Zara detention centres in Libya</u> Report 6 Dec 2023

#### National Academy of Medicine - USA [to 09 Dec 2023] https://nam.edu/programs/ News [Selected] No new digest content identified.

National Academy of Sciences - USA [to 09 Dec 2023] https://www.nationalacademies.org/newsroom? News No new digest content identified.

#### National Vaccine Program Office - U.S. HHS [to 09 Dec 2023]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates February 22-23, 2024 (Virtual)

NIH [to 09 Dec 2023]
 <u>http://www.nih.gov/</u>
 News Releases
 <u>NIH clinical trial of tuberculous meningitis drug regimen begins</u>
 December 7, 2023 — Six-month multidrug regimen being evaluated against standard treatment.

**PATH** [to 09 Dec 2023]

https://www.path.org/media-center/

Newsroom

<u>Commonwealth and PATH launch new accelerator to support climate and health</u> <u>innovations</u>

December 3, 2023 by PATH

The Commonwealth Secretariat and PATH today announced a new global accelerator to fast-track the development of promising innovations that address the extreme effects of climate change on health systems and public health across the 56 Commonwealth countries.

The Accelerator for Resilience in Climate and Health is an end-to-end accelerator platform that sources, deploys, finances, and scales innovations that help public health systems and communities mitigate, adapt to, and build resilience against the impacts of climate change...

#### Rockefeller Foundation [to 09 Dec 2023]

https://www.rockefellerfoundation.org/ Dec 03 2023 Press Releases Reaching the Last Mile Welcomes Collective Commitment To Boost Support to Community Health Workers

DUBAI | December 3, 2023 — Reaching the Last Mile – a portfolio of global health programs, investments, and initiatives working to end preventable diseases that affect the world's most vulnerable communities– welcomes ...

#### Sabin Vaccine Institute [to 09 Dec 2023]

<u>https://www.sabin.org/press/</u> Latest News & Press Releases Press Releases Global Typhoid Challenges in Focus at International Conference in Rwanda December 5, 2023

UNAIDS [to 09 Dec 2023] http://www.unaids.org/en Selected Press Releases/Reports/Statements Press statement To protect everyone's health, protect everyone's rights UNAIDS statement on the 75th anniversary of the Universal Declaration of Human Rights 10 Dec 2023

Press release

To end AIDS in Africa, UNAIDS urges governments and partners to ramp up the response to HIV

HARARE/GENEVA, 9 December 2023—Africa can end AIDS as a public threat, but to do so governments and international partners need to increase actions to reach everyone in need. Actions include accelerating treatment for children living with HIV and HIV prevention for adolescent girls, young women and key populations. Governments also need to support communities' vital leadership role in the HIV response. This was the message from UNAIDS as the 22nd International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) drew to a close...

**UNICEF** [to 09 Dec 2023]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements

Statement 09 December 2023

Statement by UNICEF Regional Director for the Middle East and North Africa Adele Khodr on the continued killing and injuring of children in the Gaza Strip and the humanitarian situation

https://www.unicef.org/press-releases/statement-unicef-regional-director-middle-east-and-north-africa-adele-khodr

AMMAN, 9 December 2023 – "The Gaza Strip is the most dangerous place in the world to be a child. Scores of children are reportedly being killed and injured on a daily basis. Entire neighborhoods, where children used to play and go to school have been turned into stacks of rubble, with no life in them. "UNICEF and other humanitarian actors have...

#### Press release 05 December 2023

More than 1 in 5 children live in poverty in 40 of the world's richest countries

https://www.unicef.org/press-releases/more-1-5-children-live-poverty-40-worlds-richest-countries FLORENCE/NEW YORK, 6 December 2023 – Some of the world's richest countries experienced sharp rises in child poverty between 2014 and 2021, according to data published today by UNICEF Innocenti – Global Office of Research and Foresight. Report Card 18: Child Poverty in the Midst of Wealth – the latest in the series looking at children's well-being...

Unitaid [to 09 Dec 2023] <u>https://unitaid.org/</u> *Featured News* 08 December 2023 <u>Unitaid announces new funding opportunities to support the elimination of vertical</u> (mother-to-child) transmission of HIV, syphilis, hepatitis B, and Chagas disease

03 December 2023

<u>Global health agency Unitaid announces ambitious goal of introducing several "climate-smart" health products by 2030 in a new climate and health strategy released on COP28</u> <u>Health Day</u>

Vaccine Equity Cooperative [nee Initiative] [to 09 Dec 2023] https://vaccineequitycooperative.org/news/ News No new digest content identified.

#### Vaccination Acceptance & Demand Initiative [Sabin) [to 09 Dec 2023]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

#### Vaccine Confidence Project [to 09 Dec 2023]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 09 Dec 2023] http://www.chop.edu/centers-programs/vaccine-education-center News No new digest content identified.

Wellcome Trust [to 09 Dec 2023] https://wellcome.ac.uk/ne ws News. Opinion, Reports No new digest content identified.

 The Wistar Institute
 [to 09 Dec 2023]

 https://www.wistar.org/news/press-releases

 Press Releases

 Dec. 6, 2023

 Wistar Scientists Identify Esophageal Cancer Biomarkers

 Dr. Noam Auslander and authors trained a neural network to identify cancer risk from microbes

World Bank [to 015 Oct 2022] http://www.worldbank.org/en/news/all All News [Selected] Global Migration in the 21st Century: Navigating the Impact of Climate Change, Conflict, and Demographic Shifts

Globally, approximately 184 million people, or 2.3% of the world population, live outside their country of citizenship. This highlights the growing complexity of human mobility, which will increasingly...

Date: December 11, 2023 Type: Feature Story

#### Putting East Asia and the Pacific on a Path to Recovery from the COVID-19 Crisis

KEY HIGHLIGHTS\$1.9 billion committed across 18 COVID-19 health response projects in the EAP region between April 2020 and October 2022.33 million vaccine doses provided to the Philippines (13 percent of...

Date: December 08, 2023 Type: Result Brief

#### PAHO, IDB and World Bank launch alliance to strengthen primary health care in the Americas

Montevideo, Uruguay, December 4, 2023– The Pan American Health Organization (PAHO), the Inter-American Development Bank (IADB) and the World Bank (WB) today launched the Alliance for Primary Health Care... Date: December 05, 2023 Type: Press Release

#### Climate Shocks: Estimates of People Exposed, Vulnerable, and at High Risk

Policy Research Working Paper: Counting People Exposed to, Vulnerable to, or at High Risk From Climate Shocks (PDF) Overview Sustained poverty reduction requires that households not only make...

Date: December 04, 2023 Type: Publication

#### New Program to Protect Millions from Rising Climate-Related Deaths and Illness

At least 21 million could die from five main health risks caused by a warmer planet DUBAI/WASHINGTON, Dec. 3, 2023 --- The World Bank announced today at COP28 a new Climate and Health Program to urgently...

Date: December 03, 2023 Type: Press Release

#### WFPHA: World Federation of Public Health Associations [to 09 Dec 2023]

https://www.wfpha.org/

Latest News –

Urgent Appeal: WFPHA Addresses WHO Executive Board on Health Conditions in Occupied Palestinian Territory

Dec 9, 2023

The World Federation of Public Health Associations (WFPHA) congratulates the initiative of the <u>World Health Organization Executive Board</u> to hold a Special Session on the health conditions in the occupied Palestinian territory.

#### World Medical Association [WMA] [to 09 Dec 2023]

https://www.wma.net/news-press/press-releases/ Press Releases No new digest content identified.

#### World Organisation for Animal Health [to 09 Dec 2023]

https://www.oie.int/en/ Press Releases, Statements No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 09 Dec 2023] https://alliancerm.org/press-releases/ Selected Press Releases FDA Approves First Gene Therapies for Sickle Cell Disease, Including First-Ever CRISPR Gene-Editing Therapy December 8, 2023 Washington, DC Today, the FDA approved two gene therapies to treat sickle cell disease, marking the biggest day in the history of gene therapy and a seminal moment in the history of biotechnology and human health.

#### **BIO** [to 09 Dec 2023]

https://www.bio.org/press-releases

Press Releases

<u>New Survey Finds Majority of Americans Support Incentivizing Biotech to Address</u> <u>Climate Change</u>

#### December 8, 2023

Most Americans Recognize that Biotech Is 'Climate Tech' A new poll from the Biotechnology Innovation Organization (BIO) shows that majorities of Americans agree that biotech plays an important role in addressing climate change and federal...

#### New BIO Poll Reveals Americans Strongly Support the Orphan Cures Act

December 7, 2023

Today, the Biotechnology Innovation Organization released a poll that shows voters overwhelmingly support the ORPHAN Cures Act, a recently introduced bill that would incentivize rare disease drug development. The...

#### DCVMN – Developing Country Vaccine Manufacturers Network [to 09 Dec 2023]

http://www.dcvmn.org/ News; Upcoming events

#### The 2nd World Local Production Forum

November 28, 2023

The 2nd World Local Production Forum: Enhancing access to medicines and other health technologies has been taking place in the Hague, Netherlands these past few days. The forum aims to leverage regional and global partnerships for local production and technology transfer for timely and equitable access worldwide.

#### ICBA – International Council of Biotechnology Associations [to 09 Dec 2023]

https://internationalbiotech.org/news/ News No new digest content identified.

IFPMA [to 09 Dec 2023] <u>https://ifpma.org/</u> Selected Press Releases/Statements Statement 7 Dec 2023 <u>6th Meeting of the Working Group on Amendments to the International Health</u> <u>Regulations (2005)</u>

On 7 December, IFPMA submitted a statement to the 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005), happening in Geneva, Switzerland.

Statement 3 Dec 2023 <u>Innovative pharmaceutical industry statement on COP28 Declaration on Climate and</u> <u>Health</u> On 3 December, ABPI, EFPIA, Farmindustria, IFPMA, IMC, JPMA, Leem, PhRMA, and vfa issued a joint statement on climate and health at the 2023 UN Conference on Climate Change, referred to as COP28. The COP28 is taking place 30 November-12 December in Dubai, UAE.

#### International Alliance of Patients' Organizations – IAPO [to 09 Dec 2023]

https://www.iapo.org.uk/news

Press and media [Selected]

IAPO's Combined Annual General Meeting (AGM) for 2022 and 2023

IAPO will hold its Annual General Meeting on Wednesday 6 December 2023 at 12.00pm GMT . This is a members only event and registration is required.

#### International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/ News No new digest announcements identified

PhRMA [to 09 Dec 2023] http://www.phrma.org/ Press Releases No new digest announcements identified

### .....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca <u>Press Releases</u> \_ - No new digest announcements identified.

Bharat Biotech <u>Press Releases</u> - No new digest announcements identified.

**BioCubaFarma** – Cuba <u>Últimas Noticias</u> - No new digest announcements identified

**Biological E** <u>News</u> - No new digest announcements identified

#### **BioNTech**

<u>Press Releases</u> 8 December 2023

BioNTech and Australia's State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem

- Multi-year partnership is aimed at strengthening the mRNA ecosystem in the State of Victoria by supporting the development of innovative medicines from research to application in the clinic
- BioNTech will set up and operate a clinical-scale mRNA manufacturing facility through the company's high-tech, digitally enabled modular manufacturing units, the BioNTainers, providing the region with capacity and know-how to manufacture investigational mRNA-based medicines

- BioNTech will establish an mRNA Innovation Center in Melbourne with the aim to curate collaboration projects with local companies and research groups
- BioNTech intends to progress the development of investigational mRNA-based medicines and other product candidates with the aim to treat up to 4,000 cancer patients in Australia and New Zealand over a ten-year period, either in clinical trials or as authorized treatments

#### 6 November 2023

#### **BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update**

- Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116
- Progress across the oncology pipeline with multiple late-stage trials initiated since third quarter start
- New and expanded strategic collaborations reflect BioNTech's commitment to delivering transformational therapies for oncology and infectious diseases
- Successful launches of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine in markets worldwide
- Updated 2023 COVID-19 vaccine revenue guidance of around €4 billion
- Guidance reduction of planned 2023 R&D expenses to €1.8-2.0 billion and SG&A expenses to €600-650 million

#### Boehringer

Press Releases

# Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials

Ingelheim, Germany, Thursday, 07/12/2023

Boehringer Ingelheim Venture Fund has invested in Obulytix, a Ghent, Belgium based spinoff from KU Leuven and Ghent University, building a novel platform based on engineered enzymes from bacteria-killing viruses (bacteriophages) as a new way to tackle antimicrobial resistant (AMR) bacterial infections.

#### CanSinoBIO

News - Website not responding at inquiry

#### CIGB

<u>Latest News</u> - No new digest announcements identified.

#### Cinnagen

<u>Recent News</u> - No new digest announcements identified.

#### Clover Biopharmaceuticals - China

<u>News</u> - No new digest announcements identified.

#### Curevac [Bayer Ag – Germany]

<u>News</u> - No new digest announcements identified.

#### Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified <u>https://sputnikvaccine.com/</u> - No new digest announcements identified

**GSK** *Press releases for media*  06 December 2023

New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions

- New IQVIA Institute for Human Data Science report, funded by GSK, explores the role of social and structural determinants of health to identify enablers and barriers to vaccine uptake in Bangkok, Brussels, Chicago, Manchester and New York City
- As one example, in both New York City and Chicago, household income, education and median house value are highly correlated with immunisation rates across all vaccines studied
- Findings to be presented today at the Global Coalition on Aging's Silver Economy Forum 2023

#### IMBCAMS, China

Home - Website not responding at inquiry.

#### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified

#### Merck

<u>News releases</u> - No new digest announcements identified

#### Moderna

<u>Press Releases</u> 12/07/2023 <u>Moderna Reviews its Environmental, Social and Governance (ESG) Progress and</u> <u>Ambitions at Second ESG Investor Event</u>

#### Nanogen

<u>News</u> - No new digest announcements identified

#### Novartis

<u>News</u> - No new digest announcements identified.

#### Novavax

<u>Press Releases</u> Dec 8, 2023 <u>Rising U.S. and EU COVID-19 Cases and Hospitalization Rates and the Need for COVID-19 Vaccination</u>

Dec 5, 2023 *COVID-19* <u>Novavax's Updated COVID-19 Vaccine Now Authorized in Canada</u>

#### Pfizer

<u>Recent Press Releases</u> - No new digest announcements identified.

#### R-Pharm

https://rpharm-us.com/index.php [No news or media page identified]

#### Sanofi Pasteur

<u>Press Releases</u> December 6, 2023

#### <u>Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record</u> <u>Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in</u> <u>Immunology</u>

- Details strong pipeline including Sanofi's record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 'pipeline-in-a-product' assets with a potential of over €5 billion peak sales..
- Ambition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines

#### Serum Institute of India

<u>NEWS & ANNOUNCEMENTS</u> - No new digest announcements identified

#### Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified [English translation function not operating]

#### Sinovac

<u>Press Releases</u> - No new digest announcements identified.

#### **SK Biosciences**

Press Releases - No new digest announcements identified.

#### Takeda

<u>Newsroom</u> - No new digest announcements identified.

#### Valneva

<u>Press Releases</u> December 4, 2023 <u>Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease</u> <u>Vaccine Candidate, VLA15</u>

December 4, 2023 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

#### Vector State Research Centre of Viralogy and Biotechnology

<u>Home</u> - Website not responding [404 error]

#### WestVac Biopharma

<u>Media</u> - No new digest announcements identified.

#### Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

.....

#### Contents [click to move among sections]

- :: <u>Milestones, Perspectives</u>
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>

:::::: :::::::

#### Journal Watch

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peerreviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>

#### **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 4 <u>https://www.tandfonline.com/toc/uabr21/current</u> [Reviewed earlier]

#### **AMA Journal of Ethics**

Volume 25, Number 11: E791-854 Nov 2023 https://journalofethics.ama-assn.org/issue/health-and-loneliness

#### Health and Loneliness

Human experiences of loneliness come from perceived deficits in social interaction. Loneliness first became a health concern due to its associations with increased mortality and functional decline, especially among elders. However, its increasing prevalence across age groups in the US calls for our health care system to pay clinical and ethical attention to loneliness as a common experience in American life. This theme issue considers loneliness as a key source of health vulnerabilities that remains underappreciated and provides insights as to how our health care system can more fully respond to the needs of patients with limited social networks.

#### **American Journal of Human Genetics**

Dec 07, 2023 Volume 110 Issue 12 p1987-2120 https://www.cell.com/ajhg/current

Year in Review

#### Genomic medicine year in review: 2023

Teri A. Manolio, et al.

Starting in 2019, AJHG has published an annual feature1,2,3,4 identifying ten key advances in applying genomic information to clinical care that were reported in the previous 12 months of published literature. The Genomic Medicine Working Group of the National Advisory Council for Human Genome Research of the National Human Genome Research Institute (NHGRI) has authored these reviews, based on its broader effort to identify notable accomplishments in genomic medicine on a monthly basis and post them on a searchable website (

https://www.genome.gov/health/Genomics-and-Medicine/accomplishments ).

Perspective

# Increasing diversity of functional genetics studies to advance biological discovery and human health

Sophia H.L. George, et al.

There is a dearth of genetic and environmental diversity in functional genomics datasets. Research focused on the variant-to-function gap aims to identify molecular QTLs but lacks data from non-European-ancestry populations. We discuss the major barriers and pose actionable suggestions, which aim to empower research and researchers from underserved populations.

#### **American Journal of Infection Control**

November 2023 Volume 51 Issue 11 p1201-1294 http://www.ajicjournal.org/current [Reviewed earlier]

#### **American Journal of Preventive Medicine**

November 2023 Volume 65 Issue 5 p763-952 <u>https://www.ajpmonline.org/current</u> [Reviewed earlier]

#### **American Journal of Public Health**

December 2023 113(12) http://ajph.aphapublications.org/toc/ajph/current Notes from the Field

Countering Mpox Vaccination Disparities in Los Angeles County, California, May– December 2022

*Infections, Immunization/Vaccines, Public Health Practice, Community Health, Race/Ethnicity* Auguste Brihn, Nava Yeganeh, Sonali Kulkarni, Olivia Moir, Saloniki Madrid, Mario Perez, Rita Singhal and Andrea A. Kim 113(12), pp. 1258–1262

#### <u>Reversing Inequity in Mpox Vaccine Distribution, Fulton County, Georgia, June–</u> <u>September 2022</u>

*Infections, Lesbian/Gay/Bisexual/Transgender Persons, Other Infections, Sexual Health, Race/Ethnicity, Notes From the Field, African Americans/Blacks* Joshua O'Neal, Jessica Lopes da Rosa, Meka Astin, David Folkes, Dewayne Crowder and David P. Holland 113(12), pp. 1263–1266

#### American Journal of Tropical Medicine and Hygiene

Volume 109 (2023): Issue 5 (Nov 2023) <u>https://www.ajtmh.org/view/journals/tpmd/109/4/tpmd.109.issue-5.xml</u> [Reviewed earlier]

#### **Annals of Internal Medicine**

November 2023 Volume 176, Issue 11 <u>https://www.acpjournals.org/toc/aim/current</u> [Reviewed earlier]

#### Artificial Intelligence – An International Journal

Volume 324 November 2023 https://www.sciencedirect.com/journal/artificial-intelligence/vol/324/suppl/C [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMC Medical Ethics**

<u>http://www.biomedcentral.com/bmcmedethics/content</u>
 (Accessed 09 Dec 2023)
 <u>Ethical considerations for biobanking and use of genomics data in Africa: a narrative</u>
 <u>review</u>
 Authors: Mary Amoakoh-Coleman, Dorice Vieira and James Abugri
 Content type: Research 5 December 2023

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 09 Dec 2023) Spatiotemporal variations of "triple-demic" outbreaks of respiratory infections in the United States in the post-COVID-19 era The US confronted a "triple-demic" of influenza, respiratory syncytial virus (RSV), and COVID-19 in the winter of 2022, leading to increased respiratory infections and a higher demand for medical supplies. It ...

Authors: Wei Luo, Qianhuang Liu, Yuxuan Zhou, Yiding Ran, Zhaoyin Liu, Weitao Hou, Sen Pei and Shengjie Lai

Citation: BMC Public Health 2023 23:2452

Content type: Research Published on: 7 December 2023

### Association between Gross National Income per capita and COVID-19 vaccination coverage: a global ecological study

*Coronavirus 2019 (COVID-19) pandemic has claimed over six million lives and infected more than* 650 million people globally. Public health agencies have deployed several strategies, including rolling out vaccin...

Authors: Dennis Ogeto Nyachoti, Pierre Fwelo, Andrew E. Springer and Steven H. Kelder Citation: BMC Public Health 2023 23:2415

Content type: Research Published on: 4 December 2023

### Acceptability of a hypothetical dengue vaccine and the potential impact of dengue vaccination on personal vector control behavior: a gualitative study in Fortaleza, Brazil

Dengue is the most rapidly spreading viral vector-borne disease in the world. Promising new dengue vaccines have contributed to a growing consensus that effective dengue control will require integrated strateg... Authors: Valerie K. Scott, Maria Suelly Nogueira Pinheiro, Marcia Maria Tavares Machado and Marcia C. Castro

Citation: BMC Public Health 2023 23:2408 Content type: Research Published on: 4 December 2023

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 09 Dec 2023) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

December 2023 - Volume 28 - 6 <u>https://ebm.bmj.com/content/28/6</u> [Reviewed earlier]

#### **BMJ Global Health**

November 2023 - Volume 8 - 11 https://gh.bmj.com/content/8/11 [Reviewed earlier]

#### **Bulletin of the Atomic Scientists**

November 2023 https://thebulletin.org/magazine/2023-11/ [Reviewed earlier]

#### **Bulletin of the World Health Organization**

Volume 101(11); 2023 Nov 1 <u>https://www.ncbi.nlm.nih.gov/pmc/issues/448753/</u> [Reviewed earlier]

#### Cell

Nov 22, 2023 Volume 186 Issue 24 p5201-5432 https://www.cell.com/cell/current [Reviewed earlier]

#### Child Care, Health and Development

Volume 49, Issue 6 Pages: 941-1111 November 2023 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

#### **Clinical Pharmacology & Therapeutics**

Volume 114, Issue 6 Pages: 1143-1387 December 2023 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current Systematic Review Open Access

Ethical Requirements for Human Challenge Studies: A Systematic Review of Reasons

Matthias Katzer, Sabine Salloch, Christoph Schindler, Marcel Mertz Pages: 1209-1219

First Published: 16 September 2023

Abstract

Human challenge studies (HCS) are controlled clinical trials in which participants are deliberately infected with a pathogen. Such trials are being developed for an increasing number of diseases. Partly as a result of the coronavirus disease 2019 (COVID-19) pandemic, there has been a recent ethical debate about the reasons for and against HCS in general, or rather, about the requirements that individual HCS must fulfill to be ethically acceptable. A systematic review was conducted to categorize and summarize such requirements and the reasons given for them. Ethics literature was searched in PubMed, Google Scholar, BELIT, and PhilPapers; eligibility criteria were articles published in a scientific/scholarly journal (original research, reviews, editorials, opinion pieces, and conference/meeting reports). Of 1,322 records identified, 161 publications were included, with 183 requirements (with associated reasons) in 10 thematic categories extracted via qualitative content analysis. In synthesizing and interpreting the requirements and their reasons, three issues emerge as particularly sensitive in the case of HCS: the meaning of the right to withdraw from research procedures, communication of researchers with the public and various stakeholders, and the conditions of informed consent. However, four other issues, not specific to HCS, stand out as the most controversial: the acceptable level of risk to participants, payment of participants, protection of vulnerable groups, and standards for international collaborations. Controversies in these areas indicate that further debate is warranted, possibly leading to more specific instructions in ethics quidance documents.

#### **Clinical Therapeutics**

November 2023 Volume 45 Issue 11 p1015-1160 <u>http://www.clinicaltherapeutics.com/current</u> [Reviewed earlier] Clinical Trials Volume 20 Issue 6, December 2023 <u>https://journals.sagepub.com/toc/ctja/20/6</u> [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 09 Dec 2023] [No new digest content identified]

#### **Contemporary Clinical Trials**

Volume 134 November 2023 <u>https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/134/suppl/C</u> [New issue; No digest content identified]

#### The CRISPR Journal

Volume 6, Issue 5 / October 2023 https://www.liebertpub.com/toc/crispr/6/5 [Reviewed earlier]

#### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023 <u>https://link.springer.com/journal/40142/volumes-and-issues/11-1</u> [Reviewed earlier]

#### **Current Medical Research and Opinion**

Volume 39, Issue 11 2023 <u>https://www.tandfonline.com/toc/icmo20/current</u> [Reviewed earlier]

#### **Current Opinion in Infectious Diseases**

December 2023 - Volume 36 - Issue 6 <u>https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx</u> [Reviewed earlier]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 09 Dec 2023] [No new digest content identified]

#### **Developing World Bioethics**

Volume 23, Issue 3 Pages: 197-292 September 2023

https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

#### **Development in Practice**

Volume 33, Issue 8, 2023 <u>http://www.tandfonline.com/toc/cdip20/current</u> [Reviewed earlier]

#### **Development Policy Review**

Volume 41, Issue 6 November 2023 <u>https://onlinelibrary.wiley.com/toc/14677679/current</u> [Reviewed earlier]

#### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022 https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latestissue [Reviewed earlier]

#### Disasters

Volume 47, Issue 4 Pages: 847-1173 October 2023 <u>https://onlinelibrary.wiley.com/toc/14677717/2023/47/4</u> [Reviewed earlier]

#### **EMBO Reports**

Volume 24 Issue 12 6 December 2023 https://www.embopress.org/toc/14693178/current [New issue; No digest content identified]

#### **Emerging Infectious Diseases**

Volume 29, Number 10—October 2023 <u>http://wwwnc.cdc.gov/eid/</u> [Reviewed earlier]

#### **Epidemics**

Volume 44 September 2023 <u>https://www.sciencedirect.com/journal/epidemics/vol/44/suppl/C</u> [Reviewed earlier]

#### **Epidemiology and Infection**

Volume 151 - 2023 <u>https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</u> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 45, Issue 6 Pages: 1-50 November–December 2023 https://onlinelibrary.wiley.com/toc/25782363/current

**Passing demands in autism research :: Women missing in phase I trials** [Reviewed earlier]

## **Ethics & International Affairs**

Volume 37 - Issue 3 - Fall 2023 <u>https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</u> [Reviewed earlier]

# Ethics, Medicine and Public Health

Volume 31 (December 2023)
 <u>https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C</u>
 *Research article Abstract only* <u>Research is a duty for health professionals and in the best interest of patients in times</u>
 <u>of a pandemic: Empirical exploration and ethical implications of the Research Ethics in</u>
 <u>Times of Pandemic (RESET-PAN) survey</u>
 T. Haaser, L. Ferretti, P.-J. Maternowski, S. Marty, ... M.-C. Saux

Article 100949

# The European Journal of Public Health

Volume 33, Issue 5, October 2023 <u>https://academic.oup.com/eurpub/issue/33/5</u> [Reviewed earlier]

# **Expert Review of Vaccines**

Vol 22 (1) 2023 <u>https://www.tandfonline.com/toc/ierv20/current</u> [Reviewed earlier]

# **Foreign Affairs**

September/October 2023 Volume 102, Number 5 https://www.foreignaffairs.com/issues/2023/102/5 [Reviewed earlier]

# Forum for Development Studies

Volume 50, 2023 - Issue 3 <u>http://www.tandfonline.com/toc/sfds20/current</u> [Reviewed earlier]

# **Genetics in Medicines**

Volume 25, Issue 12 December 2023 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12 [New issue; No digest content identified]

# **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 09 Dec 2023] [No new digest content identified]

# **Global Health Action**

Volume 16, Issue 1 (2023) <u>https://www.tandfonline.com/toc/zgha20/current?nav=tocList</u> [Reviewed earlier]

# **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 5 October 30, 2023 <u>http://www.ghspjournal.org/content/current</u> [Reviewed earlier]

## Global Legal Monitor & Legal Reports – Library of Congress/USA

<u>https://www.loc.gov/collections/global-legal-monitor/</u> https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+th e+law+library+of+congress%29&sb=date\_desc [Accessed 09 Dec 2023] [No new digest content identified]

# **Global Public Health**

Volume 18, Issue 1 (2023) <u>http://www.tandfonline.com/toc/rgph20/current</u> [Reviewed earlier]

# **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 09 Dec 2023] Challenges in international health financing and implications for the new pandemic fund The failures of the international COVID-19 response highlighted key gaps in pandemic preparedness and response (PPR). The G20 and WHO have called for additional funding of \$10.5 billion per year to adequately ... Authors: Garrett Wallace Brown, Natalie Rhodes, Blagovesta Tacheva, Rene Loewenson, Minahil Shahid and Francis Poitier Citation: Globalization and Health 2023 19:97 Content type: Research Published on: 5 December 2023

# The optimisation of public health emergency governance: a simulation study based on COVID-19 pandemic control policy

The outbreak of the COVID-19 pandemic sparked numerous studies on policy options for managing public health emergencies, especially regarding how to choose the intensity of prevention and control to maintain a...

Authors: Keng Yang and Hanying Qi Citation: Globalization and Health 2023 19:95 Content type: Research Published on: 4 December 2023

## **Health and Human Rights**

Volume 25, Issue 2, December 2023 https://www.hhrjournal.org/volume-25-issue-2-december-2023/ Special Section: Economic Inequality and the Right to Health

### Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023 <u>https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</u> **SPECIAL ISSUE: On the roof top of health policy change** [Reviewed earlier]

## **Health Policy and Planning**

Volume 38, Issue 9, November 2023 <u>https://academic.oup.com/heapol/issue/38/9</u> [Reviewed earlier]

# **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 09 Dec 2023] [No new digest content identified]

# **Human Gene Therapy**

Volume 34, Issue 21-22 / November 2023 <u>https://www.liebertpub.com/toc/hum/34/21-22</u> [Reviewed earlier]

#### **Humanitarian Practice Network**

<u>https://odihpn.org/</u> *Featured Publications* [No new digest content identified]

#### Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023 https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList [Reviewed earlier]

#### Immunity

Nov 14, 2023 Volume 56 Issue 11 p2457-2664 <u>https://www.cell.com/immunity/current</u> [Reviewed earlier]

# **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 09 Dec 2023] [No new digest content identified]

# **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 09 Dec 2023] The coverage and challenges of increasing uptake of non-National Immunization Program vaccines in China: a scoping review Non-National Immunization Program (NIP) vaccines have played an important role in controlling

*vaccine-preventable diseases (VPDs) in China. However, these vaccines are paid out of pocket and there is room to i...* Authors: Mingzhu Jiang, Shu Chen, Xuanxuan Yan, Xiaohua Ying and Shenglan Tang Citation: Infectious Diseases of Poverty 2023 12:114 Content type: Scoping Review Published on: 8 December 2023

## **International Health**

Volume 15, Issue 5, September 2023 <u>https://academic.oup.com/inthealth/issue/15/5</u> [Reviewed earlier]

# International Human Rights Law Review

Volume 12 (2023): Issue 1 (Jul 2023) https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml Table of Contents [Reviewed earlier]

# International Journal of Community Medicine and Public Health

Vol. 10 No. 9 (2023): September 2023 https://www.ijcmph.com/index.php/ijcmph/issue/view/104 [Reviewed earlier]

# **International Journal of Epidemiology**

Volume 52, Issue 5, October 2023 <u>https://academic.oup.com/ije/issue</u> [Reviewed earlier]

# International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023 https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3 Table of contents [Reviewed earlier]

# JAMA

December 5, 2023, Vol 330, No. 21, Pages 2037-2128 https://jamanetwork.com/journals/jama/currentissue Viewpoint

## **The Genetic Information Privacy Act - Drawbacks and Limitations**

Anya E. R. Prince, JD, MPP

JAMA. 2023;330(21):2049-2050. doi:10.1001/jama.2023.22345

This Viewpoint discusses proposed and enacted state legislation to protect genetic privacy for those participating in direct-to-consumer genetic testing and ensuring genetic antidiscrimination for life, health, long-term care, and disability insurance.

#### AI in Medicine

The Future of Clinical Trials - Artificial to Augmented to Applied Intelligence Adrian F. Hernandez, MD, MHS; Christopher J. Lindsell, PhD JAMA. 2023;330(21):2061-2063. doi:10.1001/jama.2023.23822

#### Editorial

#### **Innovation in Event Adjudication—Human vs Machine**

Kenneth W. Mahaffey, MD; C. Michael Gibson, MS, MD; Renato D. Lopes, MD, MHS, PhD JAMA Cardiol

## **JAMA Health Forum**

November 2023, Vol 4, No. 11 <u>https://jamanetwork.com/journals/jama-health-forum/issue</u> [Reviewed earlier]

# **JAMA Pediatrics**

December 2023, Vol 177, No. 12, Pages 1247-1364 https://jamanetwork.com/journals/jamapediatrics/currentissue Editorial Safety and Benefits of COVID-19 Vaccination in Pregnancy—Implications for the Maternal Vaccination Platform Cathering Mary Healy, MD: Lawa E. Biley, MD

Catherine Mary Healy, MD; Laura E. Riley, MD

#### Original Investigation

<u>Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During</u> <u>Pregnancy</u>

Sarah C. J. Jorgensen, PharmD, MPH; Samantha S. M. Drover, PhD; Deshayne B. Fell, PhD; et al. open access

JAMA Pediatr. 2023;177(12):1314-1323. doi:10.1001/jamapediatrics.2023.4499

This study attempts to determine if maternal mRNA COVID-19 vaccination during pregnancy is associated with adverse newborn and early infant outcomes.

#### Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years

Liang En Wee, MRCP, MPH; Nicole Tang, GCE(A); Deanette Pang, BSS; et al. JAMA Pediatr. 2023;177(12):1324-1331. doi:10.1001/jamapediatrics.2023.4505

This cohort study investigates the effectiveness of monovalent SARS-CoV-2 mRNA vaccines against Omicron infection in children younger than 5 years.

## JBI Evidence Synthesis

November 2023 Volume 73 Issue 5 p797-966 <u>https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</u> [Reviewed earlier]

## **Journal of Adolescent Health**

November 2023 Volume 73 Issue 5 p797-966 <u>https://www.jahonline.org/current</u> [Reviewed earlier]

# Journal of Artificial Intelligence Research

Vol. 78 (2023) https://www.jair.org/index.php/jair *Contents* [Reviewed earlier]

# **Journal of Community Health**

Volume 48, issue 6, December 2023 <u>https://link.springer.com/journal/10900/volumes-and-issues/48-6</u> [Reviewed earlier]

# Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. June 18, 2023 Vol 6, No 06 (2023) https://www.cmro.in/index.php/jcmro/issue/view/68 [Reviewed earlier]

#### **Journal of Development Economics**

Volume 166 January 2024 <u>https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C</u> [New issue; No digest content identified]

# Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023 <u>http://journals.sagepub.com/toc/jre/current</u> [Reviewed earlier]

# Journal of Epidemiology & Community Health

October 2023 - Volume 77 - 10 <u>https://jech.bmj.com/content/77/10</u> [New issue; No digest content identified]

#### Journal of Evidence-Based Medicine

Volume 16, Issue 3 Pages: 259-413 September 2023 <u>https://onlinelibrary.wiley.com/toc/17565391/current</u> [Reviewed earlier]

## **Journal of Global Ethics**

Volume 19, Issue 2 (2023) <u>http://www.tandfonline.com/toc/rjge20/current</u> [Reviewed earlier]

# Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 4, November 2023 https://muse.jhu.edu/issue/50808 Table of Contents [Reviewed earlier]

# Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023 <u>https://link.springer.com/journal/10903/volumes-and-issues/25-6</u> [Reviewed earlier]

# **Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 4 <u>https://www.tandfonline.com/toc/wimm20/current</u> [Reviewed earlier]

#### **Journal of Infectious Diseases**

Volume 228, Issue 5, 1 September 2023 <u>https://academic.oup.com/jid/issue/228/5</u> [Reviewed earlier]

# **Journal of International Development**

Volume 35, Issue 8 Pages: 2251-2685 November 2023 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

# **Journal of Medical Ethics**

December 2023 - Volume 49 - 12 <u>http://jme.bmj.com/content/current</u> *Editorial* <u>Equity needs to be (even) more central under the WHO Pandemic Agreement</u> (23 November, 2023) Harald Schmidt

#### Journal of Patient-Centered Research and Reviews

Volume 10, Issue 3 (2023) <u>https://institutionalrepository.aah.org/jpcrr/</u> [Reviewed earlier]

#### The Journal of Pediatrics

Volume 261, October 2023 <u>https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/261/suppl/C</u> [Reviewed earlier]

#### Journal of Pharmaceutical Policy and Practice

https://joppp.biomedcentral.com/ [Accessed 09 Dec 2023] [No new digest content identified]

#### **Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1 <u>https://journals.lww.com/jphmp/pages/currenttoc.aspx</u> [Reviewed earlier]

#### **Journal of Public Health Policy**

Volume 44, issue 3, September 2023 <u>https://link.springer.com/journal/41271/volumes-and-issues/44-3</u> [Reviewed earlier]

#### Journal of the Royal Society – Interface

December 2023 Volume 20 Issue 209 <u>https://royalsocietypublishing.org/toc/rsif/current</u> *Life Sciences–Mathematics interface Research articles*  **Population age and household structures shape transmission dynamics of emerging** <u>infectious diseases: a longitudinal microsimulation approach</u> <u>Signe Møgelmose</u>, et al. Published: 06 December 2023 Article ID:20230087

# Journal of Travel Medicine Volume 30, Issue 7, October 2023 https://academic.oup.com/jtm/issue

[Reviewed earlier]

#### Journal of Virology

Volume 97 • Number 11 • November 2023 http://jvi.asm.org/content/current

# The Lancet

Dec 09, 2023 Volume 402 Number 10418 p2167-2264 https://www.thelancet.com/journals/lancet/issue/current *Editorial* Health Day at COP28: a hard-won (partial) gain

The Lancet

Health Policy

# Rethinking how development assistance for health can catalyse progress on primary health care

Tobias Kasper, et al.

## Summary

Global campaigns to control HIV, tuberculosis, malaria, and vaccine-preventable illnesses showed that large-scale impact can be achieved by using additional international financing to support selected, evidence-based, high-impact investment areas and to catalyse domestic resource mobilisation. Building on this paradigm, we make the case for targeting additional international funding for selected high-impact investments in primary health care. We have identified and costed a set of concrete, evidence-based investments that donors could support, which would be expected to have major impacts at an affordable cost. These investments are in: (1) individuals and communities empowered to engage in health decision making, (2) a new model of people-centred primary care, and (3) next generation community health workers. These three areas would be supported by strengthening two cross-cutting elements of national systems. The first is the digital tools and data that support facility, district, and national managers to improve processes, quality of care, and accountability across primary health care. The second is the educational, training, and supervisory systems needed to improve the quality of care. We estimate that with an additional international investment of between US\$1.87 billion in a low-investment scenario and \$3.85 billion in a high-investment scenario annually over the next 3 years, the international community could support the scale-up of this evidence-based package of investments in the 59 low-income and middle-income countries that are eligible for external financing from the World Bank Group's International Development Association.

# The Lancet Child & Adolescent Health

Nov 2023 Volume 7 Number 11 p747-814, e18-e20 <u>https://www.thelancet.com/journals/lanchi/issue/current</u> [Reviewed earlier]

# Lancet Digital Health

Nov 2023 Volume 5 Number 11 e749-e847 <u>https://www.thelancet.com/journals/landig/issue/current</u> [Reviewed earlier]

# Lancet Global Health

Nov 2023 Volume 11 Number 11 e1667-e1826 <u>https://www.thelancet.com/journals/langlo/issue/current</u> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Nov 2023 Volume 23 Number 11 p1207-1322, e455-e505 <u>https://www.thelancet.com/journals/laninf/issue/current</u> [Reviewed earlier]

#### **Lancet Public Health**

Nov 2023 Volume 8 Number 11 e827-e904 <u>https://www.thelancet.com/journals/lanpub/issue/current</u> [Reviewed earlier]

#### Lancet Respiratory Medicine

Nov 2023 Volume 11 Number 11 p945-1034, e89-e95 <u>https://www.thelancet.com/journals/lanres/issue/current</u> [Reviewed earlier]

# **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023 <u>https://link.springer.com/journal/10995/volumes-and-issues/27-12</u> [Reviewed earlier]

# Medical Decision Making (MDM)

Volume 43 Issue 7-8, October-November 2023 <u>http://mdm.sagepub.com/content/current</u> [Reviewed earlier]

# The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 101, Issue 3 Pages: 637-998 September 2023 <u>https://onlinelibrary.wiley.com/toc/14680009/current</u> [Reviewed earlier]

#### **Molecular Therapy**

Dec 06, 2023 Volume 31 Issue 12 p3357-3612 <u>https://www.cell.com/molecular-therapy/current</u> *Editorials* AAV vector immunotoxicity: Stopping the domino effect

#### Aravind Asokan

Adeno-associated virus (AAV) vectors have emerged as a leading platform for therapeutic gene transfer. With a string of US Food and Drug Administration approvals (Zolgensma, Hemgenix, Roctavian, and Elevidys) and several dozen clinical trials under way, systemic AAV-based gene therapies in patients are in the spotlight.1,2,3,4 Although clinical benefits to patients are evident, there is an urgent need to understand and manage the risks posed by the immune response to AAV vectors.5

Reviews

# The state of cell and gene therapy in 2023

Daniel Chancellor, et al.

In early 2023, there were more than 100 different approved gene, cell, and RNA therapies throughout the world, with over 3,700 more in clinical and preclinical development. This review comprehensively captures the landscape for such advanced therapies, including the different genetic technologies used and diseases targeted in clinical trials.

#### Original Articles

The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products

Gloria M. Palomo, et al.

Palomo, Mariz and colleagues describe the particularities of viral vector-based gene therapy products seeking for the OD in rare non-oncological conditions. Moreover, the authors dig into the usage of regulatory incentives and how the sponsors can benefit from these schemes.

#### Nature

Volume 624 Issue 7990, 7 December 2023 <u>https://www.nature.com/nature/volumes/622/issues/7990</u> [New issue; No digest content identified]

#### **Nature Biotechnology**

Volume 41 Issue 11, November 2023 <u>https://www.nature.com/nbt/volumes/41/issues/11</u> [Reviewed earlier]

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed09 Dec 2023) [No new digest content identified]

#### **Nature Genetics**

Volume 55 Issue 12, December 2023 https://www.nature.com/ng/volumes/55/issues/12 World View 13 Nov 2023

# My Bantu vision of genomic medicine in Africa

The preparedness of Africa for genomic medicine remains a matter of debate because this question is always evaluated from a technological standpoint. Yet the resilience of African researchers and the cultural values of equity and fairness are important assets to be considered in planning for the future of genomic medicine in Africa. Aimé Lumaka

#### **Nature Human Behaviour**

Volume 7 Issue 11, November 2023 <u>https://www.nature.com/nathumbehav/volumes/7/issues/11</u> [Reviewed earlier]

# Nature Medicine

Volume 29 Issue 11, November 2023 <u>https://www.nature.com/nm/volumes/29/issues/11</u> [Reviewed earlier]

# Nature Reviews Drug Discovery

Volume 22 Issue 11, November 2023 <u>https://www.nature.com/nrd/volumes/22/issues/11</u> [Reviewed earlier]

#### **Nature Reviews Genetics**

Volume 24 Issue 12, December 2023 https://www.nature.com/nrg/volumes/24/issues/12 Comment 10 Sep 2023

#### Unequal global implementation of genomic newborn screening

In this Comment, Ahmad Abou Tayoun advocates for studies inclusive of historically underrepresented populations to ensure equitable global access to genomic newborn screening. Ahmad N. Abou Tayoun

#### Nature Reviews Immunology

Volume 23 Issue 11, November 2023 <u>https://www.nature.com/nri/volumes/23/issues/11</u> [Reviewed earlier]

#### **New England Journal of Medicine**

December 7, 2023 Vol. 389 No. 23 <u>https://www.nejm.org/toc/nejm/medical-journal</u> [New issue; No digest content identified]

#### njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 09 Dec 2023] [No new digest content identified]

## **Pediatrics**

Volume 152, Issue 5 November 2023 <u>https://publications.aap.org/pediatrics/issue/152/4</u> [Reviewed earlier]

#### PharmacoEconomics

Volume 41, issue 11, November 2023 <u>https://link.springer.com/journal/40273/volumes-and-issues/41-11</u> [Reviewed earlier]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 09 Dec 2023) [No new digest content identified]

# **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 09 Dec 2023) [No new digest content identified]

# **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate =2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 09 Dec 2023) A critical juncture for human rights in global health: Strengthening human rights through global health law reforms Benjamin Mason Meier, Luciano Bottini Filho, Judith Bueno de Mesquita, Roojin Habibi, Sharifah Sekalala, Lawrence O. Gostin

Opinion | published 08 Dec 2023 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0002663

# **PLoS Medicine**

http://www.plosmedicine.org/ (Accessed 09 Dec 2023) [No new digest content identified]

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 09 Dec 2023) [No new digest content identified]

# **PLoS One**

http://www.plosone.org/ [Accessed 09 Dec 2023] [No new digest content identified]

# **PLoS Pathogens**

http://journals.plos.org/plospathogens/ [Accessed 09 Dec 2023] [No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States** December 5, 2023 vol. 120 no. 49 <u>https://www.pnas.org/toc/pnas/120/49</u> *Special Feature* 

# The Neurobiology of Stress: Vulnerability, Resilience, and Major Depression

Social Sciences Research Article November 27, 2023Coronavirus (COVID-19) Vaccination, immunity, and the changing impact of COVID-19 on infant health Significance

The effects of COVID-19 on infant health may be among the most enduring legacies of the pandemic. Using linked population-level data on siblings born between 2014 and 2023 in birthing facilities with confirmed universal testing, we establish that maternal COVID-19 infection during pregnancy causally, and substantially, increased the risk of preterm birth—an infant outcome with lifelong consequences for health and socioeconomic well-being. We show that this effect disappeared by 2022 and demonstrate that the disappearance of this effect happened almost a year earlier in places that were early adopters of COVID-19 vaccination. The availability of vaccines and the decision to use them may have reduced a serious health burden for the next generation of US children.

#### **PNAS Nexus**

Volume 2, Issue 10, October 2023 <u>https://academic.oup.com/pnasnexus/issue/2/10</u> [Reviewed earlier]

# **Prehospital & Disaster Medicine**

Volume 38 - Issue 5 - October 2023 <u>https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</u> [Reviewed earlier]

# **Preventive Medicine**

Volume 175 October 2023 <u>https://www.sciencedirect.com/journal/preventive-medicine/vol/175/suppl/C</u> [New issue; No digest content identified]

# Proceedings of the Royal Society B

29 November 2023 Volume 290 Issue 2011 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

# **Public Health**

Volume 223 Pages e1-e16, 1-256 (October 2023) <u>https://www.sciencedirect.com/journal/public-health/vol/223/suppl/C</u> [Reviewed earlier]

# **Public Health Ethics**

Volume 16, Issue 2, July 2023 <u>http://phe.oxfordjournals.org/content/current</u> [Reviewed earlier]

# **Public Health Genomics**

2023, Vol. 26, No. 1 <u>https://karger.com/phg/issue/26/1</u> [Reviewed earlier]

# **Public Health Reports**

Volume 138 Issue 5, September/October 2023 https://journals.sagepub.com/toc/phrg/138/5 [Reviewed earlier]

# **Qualitative Health Research**

Volume 33 Issue 13, November 2023 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

#### **Research Ethics**

Volume 19 Issue 4, October 2023 <u>http://journals.sagepub.com/toc/reab/current</u> [Reviewed earlier]

#### **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 09 Dec 2023] Determinants for hesitancy in human papillomavirus (HPV) vaccine uptake among school girls in Jimma Town, Ethiopia. A mixed approach: quantitative and qualitative The human papillomavirus (HPV) vaccination helps the body fight off certain types of the virus. Despite being one of the top 10 health hazards in the world, vaccination hesitancy has received little attention ... Authors: Meron Dera, Abigiya Wondimagegnehu and Zeytu G. Asfaw Citation: Reproductive Health 2023 20:175 Content type: Research Published on: 1 December 2023

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en [No new digest content identified]

#### **Risk Analysis**

Volume 43, Issue 11 Pages: 2147-2399 November 2023 https://onlinelibrary.wiley.com/toc/15396924/current [Reviewed earlier]

#### **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 09 Dec 2023]

# Science

Volume 382| Issue 6675| 8 Dec 2023 <u>https://www.science.org/toc/science/current</u> *Policy Forum* <u>Improving equity in patent inventorship</u> BY Colleen V. Chien, Lisa Larrimore Ouellette

07 Dec 2023: 1128-1129 Expanding who gets credit for invention may boost participation in innovation

# Science and Engineering Ethics

Volume 29, Issue 6 December 2023 https://link.springer.com/journal/11948/volumes-and-issues/29-6 [Reviewed earlier]

# **Science Translational Medicine**

Volume 15| Issue 725| 6 Dec 2023 https://www.science.org/toc/stm/current [New issue; No digest content identified]

# **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 09 Dec 2023] [No new digest content identified]

# **Social Science & Medicine**

Volume 333 September 2023 <u>https://www.sciencedirect.com/journal/social-science-and-medicine/vol/333/suppl/C</u> [Reviewed earlier]

# Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 09 Dec 2023] [No new digest content identified]

# **Theoretical Medicine and Bioethics**

Volume 44, issue 5, October 2023 <u>https://link.springer.com/journal/11017/volumes-and-issues/44-5</u> [Reviewed earlier]

# Travel Medicine and Infectious Diseases

Volume 55 September–October 2023 https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/55/suppl/C

# **Tropical Medicine & International Health**

Volume 28, Issue 11 Pages: i-iv, 839-869 November 2023 <u>https://onlinelibrary.wiley.com/toc/13653156/current</u> [Reviewed earlier]

# Vaccine

Volume 41, Issue 50 Pages 7493-7580 (7 December 2023) <u>https://www.sciencedirect.com/journal/vaccine/vol/41/issue/50</u> *Short communication Abstract only* <u>Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate</u> <u>children: Exploring school-related concerns and vaccination decision-making</u> Joshua T. Sarafian, Stephanie A. Eucker, Michael Gillman, Amy M. DeLaroche, ... Brigitte M. Baumann Pages 7493-7497

#### Short communication Abstract only

Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023 Simon F. Haeder

Pages 7503-7514

Review article Abstract only <u>The path to eradication of rubella</u> Susan E. Reef, Joseph P. Icenogle, Stanley A. Plotkin Pages 7525-7531

Research article Abstract only Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea Yongjin Choi, Soohyun Park, Jinwoo Lee, Youngsung Kim, ... Ashley M. Fox Pages 7560-7572

#### Vaccines

https://www.mdpi.com/journal/vaccines [Accessed 09 Dec 2023] Latest Articles [Selected] [No new digest content identified]

# Value in Health

November 2023 Volume 26 Issue 11p1581-1674 https://www.valueinhealthjournal.com/current [Reviewed earlier]

.....

#### Contents [click to move among sections]

:: <u>Milestones, Perspectives</u> :: <u>WHO</u> :: <u>Organization Announcements</u> :: <u>Journal Watch</u> :: Pre-Print Servers

.....

# **Pre-Print Servers**

#### Gates Open Research

https://gatesopenresearch.org/browse/articles [Accessed 09 Dec 2023] Selected Research No new digest content identified.

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv [Accessed 09 Dec 2023] [Filter: All articles] Investigating the Determinants of COVID-19 Vaccine Uptake and Attitudes in Iraq: A Study Unveiling the Negative Impact of Misinformation and Vaccine Conspiracy Malik Sallam, Nariman Kareem, Mohammed Alkurtas

medRxiv 2023.12.06.23299628; doi: https://doi.org/10.1101/2023.12.06.23299628

#### Whole-genome sequencing of half-a-million UK Biobank participants

The UK Biobank Whole-Genome Sequencing Consortium, Shuwei Li, Keren J Carss, Bjarni V Halldorsson, Adrian Cortes

medRxiv 2023.12.06.23299426; doi: https://doi.org/10.1101/2023.12.06.23299426 Abstract

Whole-genome sequencing (WGS) provides a comprehensive view of the genome, enabling detection of coding and non-coding genetic variation, and surveying complex regions which are difficult to genotype. Here, we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping1 and whole-exome sequencing (WES) efforts2,3. This advance deepens our understanding of how genetics influences disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations with health-related phenotypes and identified novel genetic and clinical insights. While most genome-wide significant associations with disease traits were primarily observed in Europeans, we also identified strong or novel signals in individuals of African and Asian ancestries. Deeper capture of exonic variation in both coding and UTR sequences, strengthened and surfaced novel insights relative to WES analyses. This landmark dataset, representing the largest collection of WGS and available to the UK Biobank research community, will enable advances into our understanding of the human genome, and facilitate the discovery of new diagnostics, therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.

Impact of COVID-19 on mental illness in vaccinated and unvaccinated people: a population-based cohort study in OpenSAFELY

Venexia Walker, Praveetha Patalay, Jose Ignacio Cuitin Coronado, Rachel Denholm, Harriet Forbes, Jean Stafford, Bettina Moltrecht, Tom Palmer, Alex Walker, Ellen J Thompson, Kurt Taylor, Genevieve Cezard, Elsie MF Horne, Yinghui Wei, Marwa Al Arab, Rochelle Knight, Louis Fisher, Jon Massey, Simon Davy, Amir Mehrkar, Seb Bacon, Ben Goldacre, Angela Wood, Nishi Chaturvedi, John Macleod, Ann John, Jonathan AC Sterne

medRxiv 2023.12.06.23299602; doi: https://doi.org/10.1101/2023.12.06.23299602

# Early underdetected dissemination across countries followed by extensive local transmission propelled the 2022 mpox epidemic

Miguel I. Paredes, Nashwa Ahmed, Marlin Figgins, Vittoria Colizza, Philippe Lemey, John T McCrone, Nicola F Müller, Cécile Tran-Kiem, Trevor Bedford

medRxiv 2023.07.27.23293266; doi: https://doi.org/10.1101/2023.07.27.23293266 Revision

## COVID-19 vaccination uptake among healthcare workers in Ghana: A comprehensive analysis of knowledge, attitude, perceived vaccine effectiveness, and health belief model constructs

Whiteson Mbele, Phyllis Dako-Gyeke, Andreas Ndapewa Frans medRxiv 2023.12.05.23299475; doi: <u>https://doi.org/10.1101/2023.12.05.23299475</u>

# Understanding the key determinants of an HPV therapeutic vaccine: a modeling analysis

Jamie A. Cohen, Robyn M. Stuart, Serin Lee, Daniel J. Klein, Cliff C. Kerr, Darcy W. Rao, Haina Shin, Sharon L. Achilles

medRxiv 2023.12.04.23299403; doi: https://doi.org/10.1101/2023.12.04.23299403

# Does maternal immunization blunt the effectiveness of pertussis vaccines in infants? A systematic review and modeling study

Michael Briga, Elizabeth Goult, Tobias S Brett, Pejman Rohani, Matthieu Domenech de Cellès medRxiv 2023.06.08.23291137; doi: https://doi.org/10.1101/2023.06.08.23291137 Revision

# **OSF Pre-prints**

<u>https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences</u> [Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

# Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 09 Dec 2023] Selected Research Research Article Open Access

<u>REVISED - EIDM training as a key intervention among researchers to enhance research</u> <u>uptake and policy engagement: an evaluation study</u> [version 2; peer review: 2 approved with reservations]

# Leila Abdullahi, et al.

Abstract

The Evidence Informed Decision Making (EIDM) field has evolved faster in the past decade. This progress shows a need for capacity enhancement amongst evidence producers and evidence users in EIDM training. Through the Enhance DELTAS programme, led by the African Institute for Development Policy (AFIDEP), the project provided research uptake and policy engagement training,

mentorship and webinars to awardees of the Developing Excellence in Leadership, Training and Science (DELTAS) Africa initiative, led by the African Academy of Sciences (AAS).

Two workshops were offered to individual early career DELTAS researchers in policy engagement and evidence uptake, referred to as ENHD101, and among research leaders to enhance institutional capacity on policy engagement and evidence uptake, (ENHD102).

Overall, the programme attracted 31 early career researchers and 20 research leaders over the eight months of training, mentorship and webinars. Following the programme, the early career researchers understood the importance of EIDM for better health policies and programmes. In addition, the team appreciated the complexities of the policymaking processes as they developed the policy engagement strategy for their research. The implementation of the EIDM knowledge was reflected during the mentorship of research fellows with policy briefs as the end product.

Notably, research leaders, appreciated their role in strengthening the capacity for EIDM in decision-making spaces. Although none of the research leaders participated in strengthening the capacity for EIDM during the programme, the team anticipated improving in the long run. In addition, the research leaders developed and implemented institutional strategies for policy engagement and research uptake through the use of social media to influence policymakers.

In conclusion, the project supported the capacity building of African researchers in EIDM. It was evident that enhancing knowledge and skills on EIDM through an integrated approach to include training, mentorship, and webinars demonstrated enhanced capacity for policy engagement and evidence uptake.

#### Research Article Open Access

# **REVISED - Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries** [version 2; peer review: 3 approved with reservations]

Chelsea Modlin, Jeremy Sugarman, Gershom Chongwe, Nancy Kass, Winfred Nazziwa, Jemee Tegli, Prakriti Shrestha, Joseph Ali

#### Abstract

#### Background

Use of adaptive clinical trials, particularly adaptive platform trials, has grown exponentially in response to the coronavirus disease (COVID-19) pandemic. Implementation of these trials in lowand middle-income countries (LMICs) has been fostered through the formation or modification of transnational research partnerships, typically between research groups from LMICs and high-income countries (HICs). While these partnerships are important to promote collaboration and overcome the structural and economic disadvantages faced by LMIC health researchers, it is critical to focus attention on the multiple dimensions of partnership equity.

Methods

Based on informal literature reviews and a meeting with leaders of one of the multinational COVID-19 adaptive platform trials, we describe some important considerations about research partnership equity in this context.

#### Results

We organize these considerations into eight thematic categories: 1) epistemic structures, 2) funding, 3) ethics oversight, 4) regulatory oversight, 5) leadership, 6) post-trial access to interventions, data, and specimens, 7) knowledge translation and dissemination, and 8) research capacity strengthening and maintenance. Within each category we review normative claims that support its relevance to research partnership equity followed by discussion of how adaptive platform trials highlight new dimensions, considerations, or challenges.

#### Conclusion

In aggregate, these observations provide insight into procedural and substantive equity-building measures within transnational global health research partnerships more broadly.

#### \* \* \* \*

# <u>Think Tanks</u>

**Brookings** [to 09 Dec 2023] http://www.brookings.edu/ *Research No new digest content identified.* 

# Center for Global Development [to 09 Dec 2023]

<u>https://www.cgd ev.org/</u> *All Research [Selected] WORKING PAPERS* <u>Cost-Sharing in Medical Care Can Increase Adult Mortality: Evidence from Colombia</u> Giancarlo Buitrago et al. December 07, 2023 There is substantial evidence that cost-sharing in medical care constrains total health spending.

However, there is relatively little (and unclear) evidence on its health effects, particularly in low- and middle-income countries. This paper re-evaluates the link between outpatient cost-sharing and h...

#### Chatham House [to 09 Dec 2023] https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

# Council on Foreign Relations [to 09 Dec 2023]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

**CSIS** [to 09 Dec 2023] https://www.csis.org/ Reports [Selected] No new digest content identified.

# Kaiser Family Foundation [to09 Dec 2023]

https://www.kff.org/search/?post\_type=press-release Newsroom No new digest content identified.

# McKinsey Global Institute [to 09 Dec 2023]

https://www.mckinsey.com/mgi/overview Latest Research No new digest content identified.

#### ODI [Overseas Development Institute] [to 09 Dec 2023]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

# Pew Research Center [to 09 Dec 2023]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 09 Dec 2023] https://www.rand.org/pubs.html Published Research [Selected] No new digest content identified.

Urban Institute [to 09 Dec 2023] https://www.urban.org/publications New Research Publications - Selected

Research Report **Do No Harm Guide: Collecting, Analyzing, and Reporting Gender and Sexual Orientation Data** December 4, 2023

#### World Economic Forum [to 09 Dec 2023]

https://agenda.weforum.org/press/ Media No new digest content identified.

.....

# Public Consultations/Call for Inputs/Call for Papers

# <u>Concept paper on the development of an addendum to the Guideline on clinical</u> <u>development of vaccines on clinical trials for vaccines for immunocompromised</u> <u>individuals (PDF/185.17 KB)</u>

EMA/CHMP Reference number: /453562/2023 First published: 03/11/2023 **Consultation dates: 01/11/2023 to 01/01/2024** *Problem statement* 

The Guideline on clinical evaluation of vaccines EMEA/CHMP/VWP/164653/05 Rev. 1 (3) does not provide detailed guidance on the design of clinical trials to assess the safety, immunogenicity and efficacy of vaccines in immunocompromised individuals. There is a need to provide some guidance on potentially suitable sub-populations of immunocompromised individuals for trials to improve the extrapolation of the findings to other sub-populations. Moreover, to consider designing studies in immunocompromised individuals that not only document whether immune responses are lower than

in the immunocompetent population but also give some indication of alternative doses and/or regimens that could provide adequate levels of protection against infectious diseases.

Comments should be provided using this EUSurvey <u>form</u>. For any technical issues, please contact the <u>EUSurvey Support</u>.

# <u>Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline (PDF/177.49 KB)</u>

EMA

First published: 31/10/2023 Consultation dates: 01/11/2023 to 30/01/2024 Summary/Problem statement [Excerpt]

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this EUSurvey <u>form</u>. For any technical issues, please contact the <u>EUSurvey Support</u>

\* \* \* \* \* \* \*

*Vaccines and Global Health: The Week in Review* is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

#### :::::::

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <u>http://creativecommons.org/licenses/by/4.0/</u> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates</u> <u>Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \* \* \* \*